India, March 30 -- The article outlines UBS's Buy rating on this pharma giant, citing 22 percent upside supported by high-margin specialty drugs, a strong domestic presence, and the upcoming Semaglutide launch. It highlights the company's specialty portfolio, growth drivers, financial performance, and long-term profitability potential in global markets.

With a market capitalization of Rs 4,30,826 crore, Sun Pharmaceutical Industries Ltd's shares are trading at Rs 1,795.65 per share, up by 0.80 percent from its previous close. The company trades at a bit overvalued P/E of 35.6x compared to its Industry average, and has given a return of 206 percent in the last 5 years.

Brokerage View Sun Pharma is rated Buy with a target of Rs 2,200, off...